Phuturdex › Diseases › Hyperinsulinism
Drugs in development · updated 30 October 2026
Hyperinsulinism: drugs in development
As of 30 October 2026 there are 10 active clinical trials (recruiting or ongoing, phases I–III) on 14 drugs for hyperinsulinism. 5 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ErsodetugRZ358 | III | 2 | NCT06881992 |
| EvexomostatSDX-7320 | I–II | 1 | NCT05455619 |
| [1-13C] sodium acetate | I | 1 | NCT06354088 |
| Deuterated water | I | 1 | NCT07403604 |
| Glucose20% D-glucose | I | 1 | NCT06558422 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AlpelisibBYL719, Vijoice® | I | 2 | NCT07778524 |
| 18F-DOPA18F-FDOPA, Fluorodopa F 18 | I | 1 | NCT02021604 |
| DapagliflozinForxiga, Dapagliflozin Propanediol | I | 1 | NCT05989347 |
| DiazoxideProglycem®, Hyperstat® | I | 1 | NCT07403604 |
| GlucagonGvoke Kit®, Gvoke Hypopen® | I | 1 | NCT06558422 |
| Insulin humanMyxredlin®, Humulin R Kwikpen® | I | 1 | NCT06558422 |
| OctreotideSandostatin LAR@, Bynfezia Pen® | I | 1 | NCT06558422 |
| Recombinant Human Growth Hormone InjectionSomatropin, Human Growth Hormone | I | 1 | NCT06558422 |
| PioglitazoneActos, Pioglitazone Accord® | Early I | 1 | NCT05753657 |
Sorted by most advanced phase and number of active trials.
All 14 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Insulin resistance 41 drugs
- Obesity 233 drugs
- Metabolic syndrome 12 drugs
- Diabetes 91 drugs
- Type-1 diabetes 80 drugs
- Overweight 139 drugs
- Prediabetes 18 drugs
- Cardiovascular disease 71 drugs
- Cognitive dysfunction 94 drugs
- Inflammation 85 drugs
- Type 2 diabetes 171 drugs
- Metabolic disease 30 drugs
Broader categories
- Nutritional and metabolic diseases 5 drugs
- Metabolic disease 30 drugs
- Glucose metabolism disease 12 drugs
- Endocrine system disease 19 drugs
- Digestive System Diseases 36 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006946 “Hyperinsulinism”.